Attached files
file | filename |
---|---|
EX-99.1 - Niusule Biotech Corp. | v196713_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): September 15, 2010
Commission
file number: 333-152398
Niusule Biotech
Corp.
(Exact
Name of Registrant as Specified in Its Charter)
Nevada
|
2834
|
26-2401986
|
||
(State
or other jurisdiction of
incorporation
or organization)
|
(Primary
Standard Industrial
Classification
Code Number)
|
IRS
I.D.
|
2533 North Carson Street, Carson City,
NV
|
89706-0242
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number: 775-887-4880
N/A
(Former
Name, Former Address and Former Fiscal Year, if Changed Since Last
Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01 Regulation FD
Disclosure.
On September 15, 2010, the Company gave
the attached Corporate Presentation at the 2010 Roth Fall
Conference.
Exhibits
99.1
Corporate Presentation
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the date indicated.
NIUSULE
BIOTECH CORP.
|
|||
Date:
September 15, 2010
|
By:
|
/s/ Qinghua
Hu
|
|
Qinghua
Hu,
|
|||
Chairman
|